AD 177Alternative Names: AD-177
Latest Information Update: 11 May 2005
At a glance
- Originator Sosei R&D
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 11 May 2005 Discontinued - Preclinical for Psoriasis in United Kingdom (Transdermal)
- 11 Dec 2002 This compound is still in active development
- 04 Dec 2002 No development reported - Preclinical for Psoriasis in United Kingdom (Transdermal)